eprintid: 10113058 rev_number: 62 eprint_status: archive userid: 608 dir: disk0/10/11/30/58 datestamp: 2020-10-26 17:30:32 lastmod: 2021-12-05 00:21:10 status_changed: 2020-10-26 17:30:32 type: article metadata_visibility: show creators_name: Ray, S creators_name: Jones, R creators_name: Pritchard-Jones, K creators_name: Dzhuma, K creators_name: van den Heuvel-Eibrink, M creators_name: Tytgat, G creators_name: van der Beek, J creators_name: Oades, G creators_name: Murphy, D title: Pediatric and young adult renal cell carcinoma ispublished: pub divisions: UCL divisions: B02 divisions: D13 divisions: G22 keywords: Science & Technology, Life Sciences & Biomedicine, Oncology, Hematology, Pediatrics, pediatrics, renal cell carcinoma, targeted therapy, treatment, NEPHRON-SPARING SURGERY, LYMPH-NODE INVOLVEMENT, OPEN-LABEL, RECOMBINANT INTERLEUKIN-2, RANDOMIZED PHASE-3, COMPLETE RESPONSE, CHILDREN, THERAPY, TUMORS, EVEROLIMUS note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. abstract: Renal cell carcinoma (RCC) is rare in children but is the most common renal tumor in adults. Pediatric RCC has different clinical characteristics, histopathology, and treatment compared with adult disease. Databases were reviewed from inception to February 2020, identifying 32 publications pertaining to 350 patients under 27 years. Surgery is the cornerstone for cure in localized RCC. Lymph node dissection remains controversial. Conventional radiotherapy has no curative role in RCC; similarly, conventional chemotherapy has not proven to be effective in large cohorts. Pediatric metastatic RCC has a poor outlook. There are no published prospective studies demonstrating which adjuvant therapy could improve outcome. Sunitinib, a tyrosine kinase inhibitor, is recommended in this group despite limited evidence. This review provides an overview for pediatric RCC, including the evolving role of precision medicine. date: 2020-09-01 date_type: published publisher: WILEY official_url: https://doi.org/10.1002/pbc.28675 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1812787 doi: 10.1002/pbc.28675 lyricists_name: Dzhuma, Kristina lyricists_name: Pritchard-Jones, Kathryn lyricists_id: KDZHU50 lyricists_id: KPPRI20 actors_name: Stacey, Thomas actors_id: TSSTA20 actors_role: owner full_text_status: public publication: Pediatric Blood & Cancer volume: 67 number: 11 article_number: e28675 pages: 13 citation: Ray, S; Jones, R; Pritchard-Jones, K; Dzhuma, K; van den Heuvel-Eibrink, M; Tytgat, G; van der Beek, J; ... Murphy, D; + view all <#> Ray, S; Jones, R; Pritchard-Jones, K; Dzhuma, K; van den Heuvel-Eibrink, M; Tytgat, G; van der Beek, J; Oades, G; Murphy, D; - view fewer <#> (2020) Pediatric and young adult renal cell carcinoma. Pediatric Blood & Cancer , 67 (11) , Article e28675. 10.1002/pbc.28675 <https://doi.org/10.1002/pbc.28675>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/4/Figure%201%20flow%20chart.pdf document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/12/Supporting%20Info%20Figure%20S1.pdf document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/19/Pritchard-Jones_PBC%20Final%20Submission%2011th%20August.pdf document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/25/Pritchard-Jones_Table%201%20pt%20characteristicsDOCX.pdf document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/33/Pritchard-Jones_Supporting%20Info%20Table%20S1.pdf document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/40/Pritchard-Jones_Supporting%20Figure%20S2%20DOCX.pdf